Chronic Spontaneous Urticaria | Treatment Algorithms: Claims Data Analysis | US | 2025

The drug market for chronic spontaneous urticaria (CSU) is dominated by oral medications, including those are approved (e.g., first- and second-generation antihistamines) and used off-label (e.g., DMARDs, immunosuppressants, tricyclic antidepressants) for this disorder. However, several drug classes have serious side effects, and many patients still struggle to control their symptoms. We expect Novartis / Roche’s IgE inhibitor Xolair, the first FDA-approved biologic for CSU, to continue expanding its market share owing to the lack of efficacious, fast-acting alternatives. The leukotriene inhibitor montelukast was recently removed from CSU treatment guidelines, and we expect its prescriptions to slowly decline. Increasing off-label use of other biologics, such as Dupixent and TNF-α inhibitors, further stresses the need for newer, more-effective treatment options.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CSU patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CSU patients?
• How have the biologics Xolair and Dupixent been integrated into the treatment algorithm, and what is their source of business?
• What percentage of CSU patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of CSU patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Markets covered: United States

Key companies: Roche / Novartis, Sanofi / Regeneron, AbbVie, Amgen, Samsung Bioepis, Merck, Sandoz

Key drugs: Xyzal, Zyrtec, Benadryl, Vistaril, montelukast, Xolair, Dupixent, Allegra

Key analysis provided: Brand / therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flowcharts

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.